Sugi Predict

Sugi Predict / Compounds / SCHEMBL25758055

SCHEMBL25758055

SCHEMBL25758055

COC(=O)Cn1ncc2ccc(NC(=O)OC(C)(C)C)c(OC)c21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ GSK3B P49841 1/20 0.35
▸ DYRK1A Q13627 1/20 0.35
▸ MAPT P10636 2/20 0.34
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ TSHR P16473 2/20 0.34
▸ LMNA P02545 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ ITGA4 P13612 2/20 0.34
▸ ITGB7 P26010 2/20 0.34
▸ MAPKAPK2 P49137 1/20 0.33
▸ GPR139 Q6DWJ6 1/20 0.33
▸ SCD O00767 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ GLA P06280 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25672474 0.89 MAPK1 (0.39) KDM4EGSK3BDYRK1AMAPTITGA4
SCHEMBL31017361 0.87 GSK3B (0.37) KDM4EHSD17B10GSK3BDYRK1ANPC1
SCHEMBL25750456 0.87 GSK3B (0.37) KDM4EHSD17B10GSK3BDYRK1ANPC1
SCHEMBL30895063 0.87 MAPK1 (0.38) GSK3BDYRK1ALMNAITGA4ITGB7
SCHEMBL30895142 0.86 MAPK1 (0.38) KDM4EHSD17B10GSK3BDYRK1AMAPT
SCHEMBL31017347 0.86 MAPK1 (0.38) KDM4EHSD17B10GSK3BDYRK1AMAPT
SCHEMBL30895022 0.85 HTR2A (0.36) GSK3BDYRK1AITGA4ITGB7MAPKAPK2
SCHEMBL30895043 0.85 MAPKAPK2 (0.35) GSK3BDYRK1AITGA4ITGB7MAPKAPK2
SCHEMBL30860930 0.83 GSK3B (0.40) GSK3BDYRK1AITGA4ITGB7MAPKAPK2
SCHEMBL25756633 0.83 GSK3B (0.40) GSK3BDYRK1AITGA4ITGB7MAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 — — US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 — — US disclosed
CN-118401516-A TYK2 inhibitors, compositions and methods thereof 凌科药业(杭州)有限公司 2024-07-26 — — CN disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 — — US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 KDM4E 404/4885HSD17B10 3503/4885GSK3B 117/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 KDM4E 404/4885HSD17B10 3503/4885GSK3B 117/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 KDM4E 404/4885HSD17B10 3503/4885GSK3B 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.